Combination contraceptives: effects on weight

被引:121
作者
Gallo, Maria F. [1 ]
Lopez, Laureen M. [2 ]
Grimes, David A. [3 ]
Carayon, Florence [2 ]
Schulz, Kenneth F. [4 ,5 ]
Helmerhorst, Frans M. [6 ,7 ]
机构
[1] Ohio State Univ, Div Epidemiol, Columbus, OH 43210 USA
[2] FHI 360, Clin Sci, Durham, NC 27701 USA
[3] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[4] FHI 360, Quantitat Sci, Res Triangle Pk, NC USA
[5] UNC Sch Med, Res Triangle Pk, NC USA
[6] Leiden Univ, Med Ctr, Dept Gynaecol, Div Reprod Med, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2014年 / 01期
关键词
Administration; Cutaneous; Body Weight [drug effects; Contraceptive Agents; Female; administration; dosage; adverse effects; Contraceptives; Oral; Combined [adverse effects; Hormonal [adverse effects; Randomized Controlled Trials as Topic; Weight Gain; Humans; DOSE ORAL-CONTRACEPTIVES; 20; MU-G; G ETHINYL ESTRADIOL; COMPARATIVE CLINICAL-TRIAL; CYCLE CONTROL; MG; VAGINAL RING; G GESTODENE; G ETHINYLESTRADIOL; BODY-WEIGHT;
D O I
10.1002/14651858.CD003987.pub5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Weight gain is often considered a side effect of combination hormonal contraceptives, and many women and clinicians believe that an association exists. Concern about weight gain can limit the use of this highly effective method of contraception by deterring the initiation of its use and causing early discontinuation among users. However, a causal relationship between combination contraceptives and weight gain has not been established. Objectives The aim of the review was to evaluate the potential association between combination contraceptive use and changes in weight. Search methods In November 2013, we searched the computerized databases CENTRAL (The Cochrane Library), MEDLINE, POPLINE, EMBASE, and LILACS for studies of combination contraceptives, as well as ClinicalTrials.gov and International Clinical Trials Registry Platform (ICTRP). For the initial review, we also wrote to known investigators and manufacturers to request information about other published or unpublished trials not discovered in our search. Selection criteria All English-language, randomized controlled trials were eligible if they had at least three treatment cycles and compared a combination contraceptive to a placebo or to a combination contraceptive that differed in drug, dosage, regimen, or study length. Data collection and analysis All titles and abstracts located in the literature searches were assessed. Data were entered and analyzed with RevMan. A second author verified the data entered. For continuous data, we calculated the mean difference and 95% confidence interval (CI) for the mean change in weight between baseline and post-treatment measurements using a fixed-effect model. For categorical data, such as the proportion of women who gained or lost more than a specified amount of weight, the Peto odds ratio with 95% CI was calculated. Main results We found 49 trials that met our inclusion criteria. The trials included 85 weight change comparisons for 52 distinct contraceptive pairs (or placebos). The four trials with a placebo or no intervention group did not find evidence supporting a causal association between combination oral contraceptives or a combination skin patch and weight change. Most comparisons of different combination contraceptives showed no substantial difference in weight. In addition, discontinuation of combination contraceptives because of weight change did not differ between groups where this was studied. Authors' conclusions Available evidence was insufficient to determine the effect of combination contraceptives on weight, but no large effect was evident. Trials to evaluate the link between combination contraceptives and weight change require a placebo or non-hormonal group to control for other factors, including changes in weight over time.
引用
收藏
页数:125
相关论文
共 108 条
  • [1] A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives
    Aden, U
    Jung-Hoffmann, C
    Kuhl, H
    [J]. CONTRACEPTION, 1998, 58 (02) : 75 - 81
  • [2] AGOESTINA T, 1989, Advances in Contraception, V5, P71, DOI 10.1007/BF01849474
  • [3] Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone
    Ahrendt, Hans-Joachim
    Nisand, Israel
    Bastianelli, Carlo
    Gomez, Maria Angeles
    Gemzell-Danielsson, Kristina
    Urdl, Wolfgang
    Karskov, Birgit
    Oeyen, Luc
    Bitzer, Johannes
    Page, Geert
    Milsom, Ian
    [J]. CONTRACEPTION, 2006, 74 (06) : 451 - 457
  • [4] Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Ahrendt, Hans-Joachim
    Makalova, Dagmar
    Parke, Susanne
    Mellinger, Uwe
    Mansour, Diana
    [J]. CONTRACEPTION, 2009, 80 (05) : 436 - 444
  • [5] [Anonymous], CONSORT 2010
  • [6] Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method
    Bonny, AE
    Ziegler, J
    Harvey, R
    Debanne, SM
    Secic, M
    Cromer, BA
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (01): : 40 - 45
  • [7] Boonyarangkul Arthit, 2007, Journal of the Medical Association of Thailand, V90, P1715
  • [8] Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 mu g ethinylestradiol 75 mu g gestodene and 30 mu g ethinylestradiol 75 mu g gestodene, on lipid metabolism in an open randomized trial
    Brill, K
    Then, A
    Beisiegel, U
    Jene, A
    Wunsch, C
    Leidenberger, F
    [J]. CONTRACEPTION, 1996, 54 (05) : 291 - 297
  • [9] Brill K, 1991, ADV CONTRACEPT, V7, P51
  • [10] Burkman RT, 2007, J REPROD MED, V52, P1030